Add Nutrition and Obesities: Systemic Approaches

Nutrition-and-Obesities%3A-Systemic-Approaches.md

@@ -0,0 +1,7 @@
+<br>Laboratory headed by Prof. Karine Clément (Director) and Prof. Patricia Serradas (Vice-Director). For 20 years, our laboratory has been engaged in fundamental and applied research in the field of obesity and metabolic diseases. Cross-disciplinary programs spanning nutrition, immunity, adipose biology and data science. We investigate how lifestyle and nutrition sculpt the gut microbiota and how microbially derived signals, in turn, shape metabolic and immunoinflammatory health. Building on longitudinal human cohorts assembled over time, we map microbiome features to clinical and immune phenotypes, in close collaboration with Team 2, and launch new large-scale cohorts and nutritional intervention studies to move from association to causation. Beyond the distal gut,  [Medic GLP Official](http://cgi.www5b.biglobe.ne.jp/~akanbe/yu-betsu/joyful/joyful.cgi?page=20) we probe other ecological niches-particularly the jejunum and saliva-to determine their specific contributions to metabolic status. Observational studies relate these communities to clinical readouts, while dedicated strain banks are established from these underexplored sites to enable mechanistic work. To test causality, we perform human-to-mouse microbiota transfers and targeted experiments in rodents.<br>
+
+<br>Guided by species linked positively or negatively with host metabolic health, we evaluate probiotic candidates and assess their capacity to improve metabolic and inflammatory outcomes, paving the way for microbiome-informed nutrition and therapy. This project explores the microbiota-gut-pancreas dialogue to identify new strategies for improving metabolic health. We aim to restore incretin production and enhance beta-cell function by investigating how bacterial metabolites and gut-derived factors influence endocrine signaling in obesity and diabetes. We will study the impact of microbial metabolites on the sweet taste pathway in human enteroendocrine cells using enteroids derived from subjects with obesity, prediabetes, or type 2 diabetes. These models will allow us to evaluate incretin secretion and gene expression, offering insight into probiotic-based [therapeutic](https://www.dailymail.co.uk/home/search.html?sel=site&searchPhrase=therapeutic) approaches. In parallel, we will identify gut diffusible factors,  [MedicGLP Dietary Supplement](https://rentry.co/47026-glp-weight-loss-a-revolutionary-approach-to-obesity-management) including miRNAs and peptides, that improve insulin secretion. Using proteomic and transcriptomic analyses, in vitro islet assays, and a microfluidic organ-on-chip system, we will test their relevance after bariatric surgery in both mice and humans.<br>
+
+<br>Finally, co-culture experiments combining enteroids and pancreatic islets on microfluidic chips will clarify the mechanisms of gut-pancreas crosstalk and its role in metabolic regulation. Adipose tissue flexibility is essential for adapting to energy fluctuations and relies on the coordinated renewal of progenitor, immune, and vascular cells. In obesity, chronic lipid overload disrupts this remodeling, promoting low-grade inflammation and metabolic dysfunction. Our goal is to identify key molecular and cellular alterations driving adipose tissue impairment in severe obesity and to uncover therapeutic strategies to [restore metabolic](https://sportsrants.com/?s=restore%20metabolic) health and prevent weight regain after bariatric surgery. We will decipher how adipose progenitors contribute to fibrosis and how their fate can be redirected toward healthy adipogenesis. Parallel work examines mitochondrial dysfunction in adipocytes, focusing on glutamine metabolism and extracellular vesicle-mediated lipid signaling as drivers of systemic metabolic imbalance. Leveraging over 1,200 adipose samples from the Nutriomics biobank, we will link molecular phenotypes to clinical outcomes after bariatric surgery, identifying determinants of sustained weight loss.<br>
+
+<br>Finally, we explore cellular quality control and extracellular matrix remodeling pathways to restore adipose tissue health and improve long-term metabolic resilience. This clinically oriented topic bridges the Nutriomics research group with hospital departments of Nutrition, Diabetology, Surgery, and Gastroenterology at Pitié-Salpêtrière. Its overarching goal is to translate discoveries from fundamental research into clinical applications while building patient cohorts that, in turn, inform mechanistic studies. The focus is on developing innovative diagnostic tools, improving phenotyping, identifying predictive markers, and designing novel therapeutic strategies for obesity and diabetes. Ongoing studies aim to optimize care for genetic forms of obesity through the ObeRar and Obelisk H2022 programs, assessing long-term outcomes of treatments such as GLP-1 analogs (Wegovy) and setmelanotide. In parallel, clinical trials like DRIFTER and Diabout evaluate metabolic recovery and  [MedicGLP](https://rentry.co/47026-glp-weight-loss-a-revolutionary-approach-to-obesity-management) diabetes remission after bariatric surgery, exploring the contribution of gut microbiota and metformin response. Finally, advances in diabetology focus on multi-hormonal regulation of insulin secretion and the next generation of incretin-based therapies.<br>